Publication: A randomised controlled trial of the efficacy and safety of 0.25% desoximetasone cream (Topoxy) compared with 0.25% desoximetasone cream (Topicorte) for the treatment of scalp psoriasis
| dc.contributor.author | Leena Chularojanamontri | en_US |
| dc.contributor.author | Narumol Silpa-archa | en_US |
| dc.contributor.author | Pichanee Chaweekulrat | en_US |
| dc.contributor.author | Chayanee Likitwattananurak | en_US |
| dc.contributor.author | Puncharas Weerasubpong | en_US |
| dc.contributor.author | Natchaya Junsuwan | en_US |
| dc.contributor.author | Norramon Charoenpipatsin | en_US |
| dc.contributor.author | Chanisada Wongpraparut | en_US |
| dc.contributor.other | Faculty of Medicine, Siriraj Hospital, Mahidol University | en_US |
| dc.date.accessioned | 2020-10-05T05:42:45Z | |
| dc.date.available | 2020-10-05T05:42:45Z | |
| dc.date.issued | 2020-09-01 | en_US |
| dc.description.abstract | © 2020 Faculty of Medicine Siriraj Hospital, Mahidol University. Objective: To compare the efficacy and safety of a generic desoximetasone cream (Topoxy) with the reference form, Topicorte, for the treatment of scalp psoriasis. Methods: A randomised, double-blind, controlled study was conducted. Altogether, 105 patients with psoriasis lesions covering more than 10% of the scalp were randomised into three groups. The first, second and third groups received a placebo, Topoxy and Topicorte, respectively. The scalp psoriasis severities were assessed at weeks 0, 2, 4 and 8, using the Investigator Global Assessment (IGA) scale and Total Sign Score (TSS). The safety profiles of the products were assessed by the patients and physicians. Results: Topoxy and Topicorte were significantly more effective than the placebo in achieving at least a two-grade improvement in the IGA score from baseline at weeks 2, 4 and 8, and there were no significant differences between Topoxy and Topicorte. The TSS of both creams were significantly lower than that of the placebo at weeks 2, 4 and 8. All patients tolerated well to the therapy. Conclusion: Topoxy and Topicorte had comparable efficacies for scalp psoriasis. The medications were superior to the placebo in all parameters, and had a good safety profile. | en_US |
| dc.identifier.citation | Siriraj Medical Journal. Vol.72, No.5 (2020), 371-379 | en_US |
| dc.identifier.doi | 10.33192/SMJ.2020.50 | en_US |
| dc.identifier.issn | 22288082 | en_US |
| dc.identifier.other | 2-s2.0-85089804291 | en_US |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/123456789/59175 | |
| dc.rights | Mahidol University | en_US |
| dc.rights.holder | SCOPUS | en_US |
| dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089804291&origin=inward | en_US |
| dc.subject | Medicine | en_US |
| dc.title | A randomised controlled trial of the efficacy and safety of 0.25% desoximetasone cream (Topoxy) compared with 0.25% desoximetasone cream (Topicorte) for the treatment of scalp psoriasis | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089804291&origin=inward | en_US |
